# DESCRIPTION

## FIELD OF THE INVENTION

- introduce influenza virus replication-inhibiting peptides

## BACKGROUND OF THE INVENTION

- limitations of current influenza treatments

## SUMMARY OF THE INVENTION

- motivate new influenza antiviral agents

## DISCLOSURE OF THE INVENTION

- describe novel peptides inhibiting protein-protein interaction of PA and PB1 subunits
- describe ELISA-based screening method for identifying variant peptides
- describe peptides with amino acid sequences from both virus types A and B
- describe influenza virus replication inhibitors comprising peptides fused to cell-penetrating peptides
- describe influenza therapeutic agents comprising peptides and/or inhibitors
- describe use of peptides as tools for identifying antiviral drugs

## DETAILED DESCRIPTION

- describe virus strains and plasmid constructions

### Virus Strains

- describe virus strains used in infection experiments

### Plasmid Constructions

- describe plasmid constructions for influenza virus-like RNA and expression plasmids

### Reconstitution of the Influenza Virus Polymerase Activity

- describe reconstitution of influenza virus polymerase activity using plasmid mixture and reporter protein

### Peptide Synthesis

- describe solid-phase synthesis of peptides

### Immunoprecipitation Experiments

- describe immunoprecipitation experiments using HEK293T cells and antibodies

### Plaque Reduction Assay

- describe plaque reduction assay using MDCK cells and peptides

### ELISA

- describe ELISA using microwell plates and HA-tagged PA

### Fluorescence Polarization (FP) Assay

- describe FP assay using fluorescently labeled peptide and HA-PA

## DETAILED DESCRIPTION OF THE TABLES AND FIGURES

- describe tables showing inhibitory concentrations of FluA/FluB-derived peptides
- describe tables showing IC50 of FluA-derived PB1 peptides
- describe figures illustrating binding and inhibitory activity of peptides
- describe figures illustrating virus type-specific interaction of PA with PB1

